company background image
IBX logo

Imagion Biosystems CHIA:IBX Stock Report

Last Price

AU$0.086

Market Cap

AU$2.3m

7D

0%

1Y

-89.3%

Updated

14 Jul, 2024

Data

Company Financials

Imagion Biosystems Limited

CHIA:IBX Stock Report

Market Cap: AU$2.3m

IBX Stock Overview

Provides medical imaging technologies using magnetic resonance.

IBX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Imagion Biosystems Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Imagion Biosystems
Historical stock prices
Current Share PriceAU$0.086
52 Week HighAU$0.92
52 Week LowAU$0.073
Beta2.18
11 Month Changen/a
3 Month Changen/a
1 Year Change-89.25%
33 Year Change-97.58%
5 Year Change-95.78%
Change since IPO-98.70%

Recent News & Updates

Recent updates

Shareholder Returns

IBXAU Medical EquipmentAU Market
7D0%1.4%1.7%
1Y-89.3%23.3%9.2%

Return vs Industry: IBX underperformed the Australian Medical Equipment industry which returned 23.3% over the past year.

Return vs Market: IBX underperformed the Australian Market which returned 9.2% over the past year.

Price Volatility

Is IBX's price volatile compared to industry and market?
IBX volatility
IBX Average Weekly Movementn/a
Medical Equipment Industry Average Movement9.2%
Market Average Movement8.4%
10% most volatile stocks in AU Market17.0%
10% least volatile stocks in AU Market3.3%

Stable Share Price: IBX has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine IBX's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016n/an/aimagionbiosystems.com

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers, as well as in preclinical stage to treat prostate, ovarian, brain, and pancreatic cancer.

Imagion Biosystems Limited Fundamentals Summary

How do Imagion Biosystems's earnings and revenue compare to its market cap?
IBX fundamental statistics
Market capAU$2.29m
Earnings (TTM)-AU$12.47m
Revenue (TTM)AU$4.97m

0.5x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IBX income statement (TTM)
RevenueAU$4.97m
Cost of RevenueAU$5.25m
Gross Profit-AU$279.83k
Other ExpensesAU$12.19m
Earnings-AU$12.47m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.38
Gross Margin-5.63%
Net Profit Margin-250.95%
Debt/Equity Ratio-64.7%

How did IBX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.